HEBP2-governed glutamine competition between tumor and macrophages dictates immunotherapy efficacy in triple-negative breast cancer
Authors:
- 24 September 2025
- journal article
- Published by Elsevier in Cell Metabolism
- Vol. 37 (10) , 2030-2047.e7
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (92159301)
- National Natural Science Foundation of China (82425044)
- National Natural Science Foundation of China (U24A20736)
- National Natural Science Foundation of China (82373167)
- National Natural Science Foundation of China (82341003)
- Beijing Xisike Clinical Oncology Research Foundation (Y-MSDZD2022-0489)
- Shanghai Municipal Health Commission
This publication has 42 references indexed in Scilit:
- Distinct cellular mechanisms underlie chemotherapies and PD-L1 blockade combinations in triple-negative breast cancerCancer Cell, 2025
- Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapiesCancer Cell, 2022
- Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironmentsCancer Cell, 2022
- Single-cell analyses reveal key immune cell subsets associated with response to PD-L1 blockade in triple-negative breast cancerCancer Cell, 2021
- First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysisAnnals of Oncology, 2021
- Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trialCancer Cell, 2021
- Integrated analysis of multimodal single-cell dataCell, 2021
- Immunometabolic Interplay in the Tumor MicroenvironmentCancer Cell, 2020
- B Cells and T Follicular Helper Cells Mediate Response to Checkpoint Inhibitors in High Mutation Burden Mouse Models of Breast CancerCell, 2019
- Genomic and Transcriptomic Landscape of Triple-Negative Breast Cancers: Subtypes and Treatment StrategiesCancer Cell, 2019